TB Notes Newsletter
No. 2, 2013
NEW CDC PUBLICATIONS
Bristow CC, Dilraj A, Margot B, Podewils LJ. Lack of patient registration in the electronic TB register for sputum smear-positive patients in KwaZulu-Natal, South Africa. Tuberculosis 2013. Available online June 13, 2013.
Cegielski JP, Griffith DE, McGaha PK, Wolfgang M, Robinson CB, Clark PA, Hassell WL, Robison VA, Walker KP Jr., and Wallace C. Eliminating tuberculosis one neighborhood at a time. Am J Public Health 2013; 103: 1292–1300. doi:10.2105/AJPH.2012.300781.
Click ES, Winston CA, Oeltmann JE, Moonan PK, Mac Kenzie WR. Association between Mycobacterium tuberculosis lineage and time to sputum culture conversion. The International Journal of Tuberculosis and Lung Disease 2013 July 1; 17(7): 878-884.
Donald PR, Ahmed A, Burman WJ, Cotton MF, Graham SM, Mendel C, McIlleron H, Mac Kenzie WR, Nachman S, Schaaf HS, Starke JR, Wingfield C, Hesseling AC. Requirements for the clinical evaluation of new anti-tuberculosis agents in children. IJTLD 2013 June 1; 17(6): 794-799.
Gacek P, Sosa L, Lobato MN. New overseas screening guidelines reduce imported tuberculosis to Connecticut. Connecticut Medicine 2013; 77:325–330
Hirsch-Moverman Y, Wall K, Maiuri AM, Khan AR, Weinfurter P, Munk E, DeLuca N. Acceptability of Interferon-gamma release assays among healthcare workers who receive routine employee tuberculosis testing. International Journal of Occupational and Environmental Health 2013.
Kurbatova EV, Cavanaugh JS, Dalton T, Click E, Cegielski JP. Epidemiology of pyrazinamide-resistant tuberculosis in the United States, 1999-2009.Clinical Infectious Diseases 2013; doi: 10.1093/cid/cit452.
Kurbatova E, Kaminski D, Cegieldki P. Performance of Cepheid® Xpert MTB/RIF® and TB-Biochip® MDR in two regions of Russia with a high prevalence of drug-resistant tuberculosis. Eur J Clin Microbiol Infect Dis 2013 June 1.
Marks SM, Cronin W, Venkatappa T, Maltas G, Chon S, Sharnprapai S, Gaeddert M, Tapia J, Dorman SE, Etkind S, Crosby C, Blumberg HM, and Bernardo J. The health-system benefits and cost-effectiveness of using Mycobacterium tuberculosis Direct nucleic acid amplification testing to diagnose tuberculosis disease in the United States. Clin Infect Dis 2013 May 22; first published online May 22, 2013; doi:10.1093/cid/cit336.
Miller TL, Cirule A, Wilson FA, Holtz TH, Riekstina V, Cain KP, Moonan PK, Leimane V. The value of effective public tuberculosis treatment: an analysis of opportunity costs associated with multidrug resistant tuberculosis in Latvia. Cost Eff Resour Alloc. 2013 Apr 17;11(1):9.
Moonan PK, Teeter LD, Salcedo K, Ghosh S, Ahuja SD, Flood J, Graviss EA. Transmission of multidrug-resistant tuberculosis in the USA: a cross-sectional study. Lancet Infect Dis. 2013 Jun 4. doi:pii: S1473-3099(13)70128-2. 10.1016/S1473-3099(13)70128-2. [Epub ahead of print.]
Oramasionwu GE, Heilig CM, Udomsantisuk N, Kimerling ME, Eng B, Nguyen HD, Thai S, Keo C, McCarthy KD, Varma JK, Cain KP. The utility of stool cultures for diagnosing tuberculosis in people living with the human immunodeficiency virus. Int J Tuberc Lung Dis 2013 Aug. 1; 17(8): 1023-1028. http://dx.doi.org/10.5588/ijtld.13.0061
Sable SB. PD-1 lives up to its reputation in active tuberculosis. Online publication. 2013 May 9; J Infect Dis.
Yelk Woodruff RS, Winston CA, Miramontes R. Predicting U.S. tuberculosis case counts through 2020. PLoS ONE 8(6) June 13, 2013; e65276. doi:10.1371/journal.pone.0065276.